Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497072 | 1.00 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7418023 | 1.00 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL5187344 | 0.97 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL5188450 | 0.97 | CTSK (0.47) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL9327711 | 0.96 | CTSK (0.48) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7438556 | 0.95 | CTSK (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7331165 | 0.95 | POLB (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL6622988 | 0.95 | POLB (0.46) | CTSKPOLBGAAMAPTXBP1 | |
| Potassium Ion SCHEMBL7455208 | 0.90 | POLB (0.44) | CTSKPOLBGAAMAPTXBP1 | |
| SCHEMBL7419487 | 0.86 | SYK (0.52) | CTSKPOLBTDP1SYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| US-5594006-A | SUCH AS COLLEGENASE, STROMELYSIN; ANTICANCER AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641323-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| WO-1994021612-A1 | CARBOSTYRIL DERIVATIVES AS MATRIX METALLOPROTEINASES INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | CTSK 112/4885POLB 2980/4885GAA 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.